Paxlovid for LTC DSL


The eligibility for COVID-19 patients to access the outpatient treatment, Paxlovid, has been expanded to include residents of Long-Term Care and most Designated Supportive Living sites. Paxlovid can be prescribed by a physician or nurse practitioner to any resident of Long-Term Care or Designated Supportive Living 4 or 4D who has tested positive for COVID-19 regardless of vaccination status.

Consent Form

Copy / paste the below text into the "Details of Treatment Plan or Procedure" field in the consent form.

Paxlovid Treatment for COVID-19 - Treatment is being offered to reduce the chance of severe COVID-19 infection and to reduce the chance of hospitalization. Paxlovid has interactions with other drugs that may mean it is not for you. Your doctor and/or pharmacist will review your medications to look for these interactions before Paxlovid is prescribed. The side effects of Paxlovid are mild and consist mainly of headache, altered sense of taste, vomiting and diarrhea. Allergic reactions to Paxlovid are rare. Please follow up at your site if you have any concerns with Paxlovid. I have been provided with a copy of the FAQs for Long-Term Care/Designated Supportive Living Residents (April 7, 2022).

Quick Reference